Elements of the TIMI

The TIMI risk score was designed, developed and validated in cohorts with patients with ACS [3-5]. It is useful to determine prognosis and treatment. The higher the score, the higher the adverse event rate. See Fig 1 for the prognostic value of the TIMI risk score.

Fig 1

The TIMI risk score can also identify patients that will benefit from certain interventions (e.g. Glycoprotein IIb/IIIa Receptor Inhibitors (GpIIb/IIIa Inhibitors) and early percutaneous coronary intervention): the higher the risk, the greater the benefit from these interventions. See Fig 2 for the TIMI risk score and Tirofiban (GpIIb/IIIa Inhibitor) benefit.

Fig 2

Learning bite

In contrast to patients with STEMI, risk stratification in patients with NSTE-ACS not only determines prognosis but also directly influences early treatment options.